Quarterly Product Revenue Up 66% Year-Over-Year
On Track for Potential FDA Clearance of T2Bacteria Panel in the Second Quarter 2018
LEXINGTON, Mass., May 08, 2018 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today operating highlights and financial results for the first quarter ended March 31, 2018.
First Quarter Business and Financial Performance Highlights:
Reported first quarter total revenue of $2.311 million, up 146% year-over-year.
Reported first quarter product revenue of $1.048 million, up 66% year-over-year.
READ FULL TEXT